Thank you for your thoughtful questions. Obviously I don't know the answer to your question. I think the question around the future of immune therapy in bladder cancer and kidney cancer, which I know a little bit about, and the future beyond that is very different in the two diseases. I see, bladder cancer. I see us curing a large proportion of patients with bladder cancer with the drugs that we currently have. I genuinely think that's true. And I，you know，I think perioperative disease will kill patients. I said that five minutes ago. I think maybe ADC combinations with immune therapy, we talk a little bit about that. But there's a drug, there's a HER2 drug T-DXd, which I didn't talk about in HER2 high bladder cancer, that's got great activity. Combine that with enfortumab vedotin that might work with pembrolizumab as a triplet. that could cure bladder cancer, a lot of bladder cancer. So I think there is an opportunity.

The story of the second generation of immune therapies in kidney cancer is much more complicated and is less impressed. I'm going to talk a little bit about immune therapy in kidney cancer tomorrow, nivolumab、pembrolizumab particularly those two drugs have transformed kidney cancer. If Avelumab seems to help a little bit, but I'm not sure how much some people feel a lot. I think most of the work is being done by pembrolizumab and nivolumab. The second generation of immune therapies is not being successful. The OX-40s, the CS-1s. I could go on the IL-2s. We're currently doing the IL-2 study. So there is much hope for cellar therapies. There's a cellar therapy trial. There's a CAR-T study in the not too distant future that's gonna be presented. There are some other second generation of immune therapies that are being explored, LAG-3/TIGIT…… 

My experience of these would use these in our hospital is they haven't been overwhelming. So while the second generation of antibody drug conjugates are exploding in bladder cancer that will cure the disease, I think we are reaching a plateau with immune therapy in kidney cancer. So it's interesting to be revolved in two diseases, because five years ago it was the opposite, we had all this hope in kidney cancer, but bladder cancer was not moving. And now it's the other way around.